drugset / Trial / NCT06160414

A Study to Investigate the Potential Drug Interactions Between ALXN2080 and Rosuvastatin and Metformin in Healthy Adult Participants

NCT06160414

Phase 1 Completed 20 enrolled Alexion Pharmaceuticals, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The primary objectives of this study are to determine the effect of multiple doses of ALXN2080 on the single-dose PK of rosuvastatin and to determine the effect of multiple doses of ALXN2080 on the single-dose PK of metformin.

Timeline

Start
2023-04-12
Primary completion
2024-02-05
Completion
2024-02-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule Oral
Subject Rosuvastatin Small molecule Oral
Subject ZORACOPAN Small molecule Oral

Indications

No indication recorded.